Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79910.070.087%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

BridgeBio Pharma Inc

BBIONASDAQ
Trade with Public
Trade with Public
$74.84
-0.57-0.76%
At close: Sep 4, 5:00 PM EST
$74.84
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 9 Quarters

Analyst Consensus — 25 Analysts

23Buy
2Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$91Upside to Avg. PT+22.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 2, 2026HC Wainwright & Co.Raghuram SelvarajuMaintainedBuy$120
Sep 1, 2026MizuhoSalim SyedPT RaiseOutperform$96→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved